Sunday 18 October 2026 Export BIOLQ’s income statement to Excel — free account

Biolase, Inc.

Biolase, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $49.2 million, up 1.45% from fiscal 2022. Revenue growth for five consecutive years, operating cash flow growth for three.

0.00 0.00 NaN

Follow BIOLQ

Alert me

Market cap: $2.3M
P/E: 0.0×
Fwd P/E: −0.2×
Dividend yield: —
F-score: 3/9
Altman Z: −12.72
Beneish M: −3.44
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 7.80%

Capital & Financial Ratios $m

Market Cap 2.33

Revenue 46.03

Net Income (16.04)

Free Cash Flow (13.14)

Net Debt 12.60

Current Ratio 0.63

Debt/Equity (3.29)

P/E ratio 0.00

Fwd P/E (0.15)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 92.90%

Next Y EPS Growth 79.50%

Next Y revenue growth 23.83%

Next 5Y EPS Growth 20.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

EV/Sales against its own 10 years 27.33%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2021	2022	2023	Q'24
Cash	30	4	7	3
Receivables	4	6	5	4
Inventory	13	16	11	10
Other	—	—	—	—
	49	29	25	19

	2021	2022	2023	Q'24
Payables	3	6	6	3
ST’ Debt	0	1	2	16
Other	—	—	—	1
	14	18	20	31

Compound Annual Growth %

	10y	5y	3y
Sales	(1.37%)	1.27%	29.23%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(13.64%)	(29.32%)	(42.01%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	10	12	11	—	—
’23	10	14	11	13	49
’22	10	12	12	14	48
’21	8	9	10	12	39
’20	5	3	7	9	23
’19	10	9	9	10	38
’18	10	12	11	13	46

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(1)	(4)	—	—
’23	(6)	(4)	(3)	(2)	(14)
’22	(8)	(7)	(7)	(6)	(27)
’21	(6)	(4)	(4)	(3)	(17)
’20	(4)	(5)	(2)	(1)	(13)
’19	(5)	(2)	(1)	(5)	(13)
’18	(5)	(4)	(2)	(4)	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(1)	(4)	—	—
’23	(6)	(4)	(3)	(2)	(15)
’22	(8)	(7)	(9)	(6)	(30)
’21	(7)	(4)	(4)	(3)	(17)
’20	(4)	(5)	(2)	(1)	(13)
’19	(5)	(2)	(1)	(5)	(13)
’18	(5)	(4)	(2)	(4)	(15)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.36)	(0.08)	(0.04)	—	—
’23	(18.00)	(8.93)	(3.89)	(1.76)	(29.44)
’22	(81.00)	(91.00)	(110.00)	(128.00)	(416.00)
’21	(150.00)	(11.65)	(50.00)	(75.00)	(275.00)
’20	(475.00)	(300.00)	(525.00)	(175.00)	(1.40k)
’19	(575.00)	(450.00)	(625.00)	(325.00)	(1.92k)
’18	(625.00)	(600.00)	(575.00)	(825.00)	(2.62k)

Fiscal quarters ending in the months shown.

Group	Line	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e
Price, $
Price, $	Low	—	—	8,330.94	3,500.00	2,275.00	1,075.00	527.50	925.00	51.30	1.07	Analyst estimates 2024–2026 Powerpack
	High	—	—	23,232.76	21,942.05	7,450.00	7,175.00	2,400.00	3,775.00	1,175.00	76.00
People
People	Employees	—	—	225	195	190	157	135	161	192	157
	Revenue/emp, $m	—	—	0.23	0.24	0.24	0.24	0.17	0.24	0.25	0.31
Income, $m
Income, $m	Revenue	—	—	52	47	46	38	23	39	48	49
	Gross margin, %	—	—	39.20	32.23	36.60	37.80	27.10	42.18	32.83	34.02
	EBT	—	—	(15)	(17)	(21)	(18)	(17)	(16)	(29)	(21)
	EBT margin, %	—	—	(29.38)	(37.15)	(46.48)	(47.35)	(73.31)	(41.07)	(58.86)	(41.90)
	Net income	—	—	(15)	(17)	(22)	(18)	(17)	(16)	(29)	(21)
	Depreciation	—	—	1	1	1	1	1	1	2	3
Per share, $
Per share, $	Revenue	—	—	10,573.47	7,953.56	5,628.66	4,064.41	929.80	664.20	702.35	38.47
	Earnings	—	—	(3,625.00)	(3,500.00)	(2,625.00)	(1,925.00)	(1,400.00)	(275.00)	(416.00)	(29.44)
	Cash flow	—	—	(2,162.45)	(3,120.68)	(1,725.24)	(1,370.54)	(522.24)	(283.22)	(387.84)	(11.03)
	Capex	—	—	(288.57)	(126.61)	(63.66)	(22.26)	(3.92)	(11.98)	(54.01)	(0.88)
	Free cash flow	—	—	(2,451.02)	(3,247.29)	(1,788.90)	(1,392.80)	(526.16)	(295.20)	(441.86)	(11.91)
	Book value	—	—	4,503.06	4,959.32	1,352.32	466.88	409.31	427.25	70.86	1.53
	Shares, m	—	—	0	0	0	0	0	0	0	1
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	1.63	0.66	0.44	0.34	1.12	1.47	0.10	0.03
	P/B	—	—	3.83	1.06	1.83	34.09	2.58	2.29	1.00	0.00
	EV/Sales	—	—	1.52	0.48	0.57	0.53	1.06	1.06	0.30	0.18
	EV/FCF	—	—	(6.55)	(1.17)	(1.78)	(1.56)	(1.87)	(2.37)	(0.48)	(0.58)
Cash, $m
Cash, $m	Operating cash flow	—	—	(11)	(18)	(14)	(13)	(13)	(17)	(27)	(14)
	Capex	—	—	(1)	(1)	(1)	0	0	(1)	(4)	(1)
	Free cash flow	—	—	(12)	(19)	(15)	(13)	(13)	(17)	(30)	(15)
Balance, $m
Balance, $m	Working capital	—	—	16	23	17	1	24	36	11	5
	Total debt	—	—	0	—	11	13	16	14	14	14
	Net debt	—	—	(9)	(12)	2	7	(1)	(16)	10	7
	Shareholders’ equity	—	—	22	29	11	4	10	25	5	2
Returns, %
Returns, %	ROA	—	—	(41.70)	(49.05)	(52.80)	(50.75)	(93.88)	(34.69)	(61.73)	(102.66)
	ROIC	—	—	(71.66)	(64.93)	(96.20)	(83.37)	(134.04)	(113.59)	(109.22)	(118.79)
	ROE	—	—	(74.72)	(81.17)	(106.65)	(311.44)	(665.05)	(95.22)	(191.94)	(1,620.81)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Sep 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADGM Adagio Medical Holdings, Inc.	$2.8M	— (loss-making)	—	−33.50% (below 0%: shrinking)	n/m	−12.86% (below 0%: shrinking)	0.00%	0.00%	Compare
IVF INVO Fertility, Inc	$2.8M	0.0×	— (loss-making)	+16.73% (above 0%: growing)	n/m	+35.07% (above 0%: growing)	35.06%	(59.28%)	Compare
NXL Nexalin Technology, Inc.	$2.6M	— (loss-making)	— (loss-making)	−82.72% (below 0%: shrinking)	n/m	−97.23% (below 0%: shrinking)	72.95%	(18,420.49%)	Compare
BIOLQ Biolase, Inc.	$2.3M	— (loss-making)	— (loss-making)	−0.65% (below 0%: shrinking)	n/m	−60.22% (below 0%: shrinking)	40.39%	(6.41%)
XAIR Beyond Air, Inc.	$2.2M	— (loss-making)	— (loss-making)	+0.45% (above 0%: growing)	n/m	−9.10% (below 0%: shrinking)	12.73%	(373.98%)	Compare
NUVOQ Holdco Nuvo Group D.G Ltd.	$2.1M	— (loss-making)	—	—	n/m	−1.05% (below 0%: shrinking)	0.00%	0.00%	Compare
VJET Flyte Aviation, Inc.	$2.1M	— (loss-making)	— (loss-making)	+380.66% (above 0%: growing)	n/m	−26.70% (below 0%: shrinking)	9.62%	(388.13%)	Compare
NUWE Nuwellis, Inc.	$2.0M	— (loss-making)	— (loss-making)	+14.14% (above 0%: growing)	n/m	−51.55% (below 0%: shrinking)	76.08%	(160.94%)	Compare
AFIB Acutus Medical, Inc.	$1.7M	— (loss-making)	— (loss-making)	+204.18% (above 0%: growing)	n/m	+76.40% (above 0%: growing)	14.20%	(3.81%)	Compare
Median of peers	$2.2M	—	—	+14.14%	—	−10.98%	13.47%	(110.11%)

All 149 Medical Devices stocks →

Biolase, Inc. (BIOLQ) key facts

Strength: Biolase, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $49.2 million, up 1.45% from fiscal 2022.
Biolase, Inc. (BIOLQ) is a Medical Devices company in the Healthcare sector.
Return on equity was −1,620.8% and debt-to-equity -3.29.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −12.72 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.